• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, January 19, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a

Bioengineer by Bioengineer
October 7, 2020
in Cancer
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: ©Takaaki Konuma

Myelodysplastic syndrome (MDS) is a bone marrow failure disorder characterized by intractable cytopenia and dysplastic hematological changes. MDS has a varied clinical course, with some patients remaining asymptomatic with mild cytopenia for a long time, while others show progressive leukemia a short time after the diagnosis. Allogeneic hematopoietic cell transplantation (*1) is considered the only curative treatment.

A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect (*2) of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients. In addition, they succeeded in identifying a category of patients for whom the GVT effect was identified. These results used data from 3119 MDS patients aged 16 to 70 who are registered at the Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT).

These results were published online in Clinical Cancer Research, a journal of the American Association for Cancer Research on September 7.

Graft-versus-tumor effect associated with limited chronic GVHD alone improved survival in high-risk MDS

According to Assistant Professor Konuma, the research group retrospectively evaluated the impact of acute and chronic graft-versus-host disease (GVHD) (*3) on transplant outcomes for a large cohort of adult patients with a low-risk (n = 1193) or high-risk (n = 1926) of myelodysplastic syndrome (MDS).

Their study demonstrated that for patients with a low-risk of MDS, acute and chronic GVHD at any grade or severity did not improve overall mortality, relapse, or non-relapse mortality (NRM). For patients with a high-risk of MDS, the favorable effect of limited chronic GVHD on disease relapse was associated with a decrease in overall mortality; however, the favorable effects of grade III-IV acute GVHD, or extensive chronic GVHD on disease relapse were offset by increased NRM.

Importantly, the graft-versus-tumor effect associated with limited chronic GVHD alone improved survival in those at high-risk of MDS. This GVT associated GVHD could be the explanation for the fact that excessive immune reactions, as they become clinically visible with severe GVHD, ultimately have negative effects.

###

For details of the research, please see the paper.

Assistant Professor Konuma described the research as “a large-scale clinical study targeting improved treatment of MDS and development of cancer immunotherapy.”

(*1) Allogeneic hematopoietic cell transplantation

The treatment of recipients with irradiation and/or high-dose chemotherapy followed by the infusion of cells containing haematopoietic stem and progenitor cells, such as bone marrow, cytokine-mobilized peripheral blood or umbilical cord blood. It also can mediate graft­versus­tumour (GVT) effects in which donor­derived immune cells attack the host tumours, along with irradiation and/or high-dose chemotherapy for host tumors.

(*2) Graft-versus-tumor (GVT) effect

A phenomenon in which malignant host cells are attacked by donor immune cells. Clinically, it is augmented in patients with graft-versus-host disease.

(*3) Graft-versus-host disease (GVHD)

A complication mediated by host alloantigen- activated donor T cells attacking the normal tissues of the host after allogeneic hematopoietic cell transplantation.

Media Contact
Takaaki Konuma
[email protected]

Original Source

https://www.ims.u-tokyo.ac.jp/imsut/en/about/press/page_00019.html

Related Journal Article

http://dx.doi.org/10.1158/1078-0432.CCR-20-1104

Tags: cancerHematologyImmunology/Allergies/AsthmaInternal MedicineMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Tool that predicts if chemotherapy will produce debilitating side effects in older adults

January 14, 2021
IMAGE

New insights into pancreatitis

January 14, 2021

Bladder cancer — When to use chemotherapy

January 14, 2021

Study shows sharp decline in cancer screenings, diagnoses during the first COVID-19 surge

January 14, 2021
Next Post
IMAGE

UC Davis School of Medicine and UTHealth get nearly $54 million for dementia research

IMAGE

Grant awarded to study how plants affect microbiomes

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    53 shares
    Share 21 Tweet 13
  • Blood pressure drug may be key to increasing lifespan, new study shows

    44 shares
    Share 18 Tweet 11
  • New drug form may help treat osteoporosis, calcium-related disorders

    39 shares
    Share 16 Tweet 10
  • People living with HIV face premature heart disease and barriers to care

    59 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

MaterialsGeneticsBiologyClimate ChangeChemistry/Physics/Materials SciencesMedicine/HealthInfectious/Emerging DiseasesEcology/EnvironmentTechnology/Engineering/Computer SciencecancerPublic HealthCell Biology

Recent Posts

  • A clinical trial provides encouraging results on ivermectin for reducing mild COVID-19
  • New approach emerges to better classify, treat brain tumors
  • New drug combination shows promise as powerful treatment for AML
  • Green med diet cuts non-alcoholic fatty liver disease by half – Ben-Gurion U. study
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In